Nature Search

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

The DNA repair enzymeO⁶-methylguanine-DNA methyltransferase (MGMT) antagonizes the effects of alkylating agents, and its expression is associated with resistance to cancer therapy based on these compounds. Weller et al. consider the prognostic and predictive value of MGMT gene silencing in gliomas and describe the assays that are commonly used to evaluate MGMT status, focusing particularly on MGMT promoter methylation, which is the key mechanism of MGMTgene silencing.

Michael Weller
Roger Stupp
Monika E. Hegi
Reviews08 Dec 2009
Nature Reviews Neurology

Volume: 6, P: 39-51
INK4a/Arf is required for suppression of EGFR/ΔEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma

Yan Lachat
Annie-Claire Diserens
Monika E Hegi
Research26 Jul 2004
Oncogene

Volume: 23, P: 6854-6863
Targeting brain-tumor stem cells

Compounds that act on mechanisms associated with resistance of glioblastoma stem cells show efficacy in mouse models.

Roger Stupp
Monika E Hegi
News & Views01 Feb 2007
Nature Biotechnology

Volume: 25, P: 193-194
Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant

Michael A Klein
Daniela Rüedi
Monika E Hegi
Research09 Nov 2000
Oncogene

Volume: 19, P: 5329-5337
p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma

Giulia Fulci
Martin Labuhn
Erwin G Van Meir
Research28 Jul 2000
Oncogene

Volume: 19, P: 3816-3822
Molecular characterization leads the way

In 2012, advances in molecular profiling of primary brain tumours allowed identification of subgroups of glioma and medulloblastoma that were associated with distinct prognoses and predicted treatment response. Adjuvant chemotherapy is now established for 1p/19q co-deleted anaplastic oligodendrogliomas, and may be the preferred treatment in elderly patients with glioblastoma with a methylated MGMT promoter.

Roger Stupp
Monika E. Hegi
News & Views08 Jan 2013
Nature Reviews Clinical Oncology

Volume: 10, P: 69-70
Retraction Note: Marker-independent identification of glioma-initiating cells

Virginie Clément
Denis Marino
Ivan Radovanovic
Amendments and Corrections27 Sept 2013
Nature Methods

Volume: 10, P: 1035
Quantitative real-time PCR does not show selective targeting of p14^ARF but concomitant inactivation of both p16^INK4A and p14^ARF in 105 human primary gliomas

Martin Labuhn
Graham Jones
Adrian Merlo
Research09 Apr 2001
Oncogene

Volume: 20, P: 1103-1109
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis

Klemm et al. show that resistance to CSF1R inhibition in breast cancer brain metastasis is driven by compensatory activation of the CSF2Rb–STAT5 axis in macrophages, which can be alleviated by combined targeting of CSF1R and STAT5.

Florian Klemm
Aylin Möckl
Lisa Sevenich
Research18 Oct 2021
Nature Cancer

Volume: 2, P: 1086-1101
In search of molecular markers of glioma in elderly patients

Elderly patients represent a growing proportion of individuals with malignant glioma, but are often excluded from trials owing to their poor prognosis. In a new study, researchers have investigated molecular markers of glioma specifically in elderly patients—are these markers of clinical use?

Monika E. Hegi
Roger Stupp
News & Views02 Jul 2013
Nature Reviews Neurology

Volume: 9, P: 424-425
Retracted: Marker-independent identification of glioma-initiating cells

Tumor-initiating cells can be isolated from human glioma or from glioma cultures based on cellular autofluorescence and morphological features alone.

Virginie Clément
Denis Marino
Ivan Radovanovic
Research21 Feb 2010
Nature Methods

Volume: 7, P: 224-228
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation

Joyce and colleagues use bulk and single-cell profiling of T cell phenotypes in human samples from primary brain tumors and brain metastases as a resource for understanding the biology and therapeutic relevance of the brain tumor microenvironment.

Vladimir Wischnewski
Roeltje R. Maas
Johanna A. Joyce
ResearchOpen Access22 May 2023
Nature Cancer

Volume: 4, P: 908-924
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Michael Weller
Martin van den Bent
Wolfgang Wick
Amendments and CorrectionsOpen Access23 Mar 2022
Nature Reviews Clinical Oncology

Volume: 19, P: 357-358
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1

Michele Albertoni
Phillip H Shaw
Monika E Hegi
Research14 Jun 2002
Oncogene

Volume: 21, P: 4212-4219
Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain

Kristen Jones
Clare Keddy
Monika A. Davare
ResearchOpen Access27 Sept 2024
Scientific Reports

Volume: 14, P: 1-14
Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison

Tim De Meyer
Pierre Bady
Wim Van Criekinge
ResearchOpen Access20 Oct 2015
Scientific Reports

Volume: 5, P: 1-13
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression

Alessandro Tancredi
Olga Gusyatiner
Monika E. Hegi
ResearchOpen Access13 Dec 2022
Cell Death & Disease

Volume: 13, P: 1-12
Hyperpolarized ¹³C-glucose magnetic resonance highlights reduced aerobic glycolysis in vivo in infiltrative glioblastoma

Mor Mishkovsky
Olga Gusyatiner
Monika E. Hegi
ResearchOpen Access11 Mar 2021
Scientific Reports

Volume: 11, P: 1-9
Erratum: INK4a/Arf is required for suppression of EGFR/ΔEGFR(2–7)-dependent ERK activation in mouse astrocytes and glioma

Yan Lachat
Annie-Claire Diserens
Monika E Hegi
Amendments and Corrections03 Feb 2005
Oncogene

Volume: 24, P: 1128
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Herein, the European Association of Neuro-Oncology (EANO) provides recommendations for the diagnosis, treatment and follow-up of adult patients with diffuse gliomas. These evidence-based guidelines incorporate major changes in diagnostic algorithms based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System as well as on evidence from recent large clinical trials.

Michael Weller
Martin van den Bent
Wolfgang Wick
ReviewsOpen Access08 Dec 2020
Nature Reviews Clinical Oncology

Volume: 18, P: 170-186
An integrated pipeline for comprehensive analysis of immune cells in human brain tumor clinical samples

Bulk tumor preservation and dissociation enable multiple analyses of the brain tumor immune microenvironment via immunofluorescent staining and cell sorting followed by transcriptomics, genomics or in vitro culture of specific cell populations.

Roeltje R. Maas
Klara Soukup
Johanna A. Joyce
Protocols30 Aug 2021
Nature Protocols

Volume: 16, P: 4692-4721
WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1

I Vassallo
P Zinn
M E Hegi
Research16 Mar 2015
Oncogene

Volume: 35, P: 12-21

Search

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

INK4a/Arf is required for suppression of EGFR/ΔEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma

Targeting brain-tumor stem cells

Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant

p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma

Molecular characterization leads the way

Retraction Note: Marker-independent identification of glioma-initiating cells

Quantitative real-time PCR does not show selective targeting of p14^ARF but concomitant inactivation of both p16^INK4A and p14^ARF in 105 human primary gliomas

Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis

In search of molecular markers of glioma in elderly patients

Retracted: Marker-independent identification of glioma-initiating cells

Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation

Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain

Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression

Hyperpolarized ¹³C-glucose magnetic resonance highlights reduced aerobic glycolysis in vivo in infiltrative glioblastoma

Erratum: INK4a/Arf is required for suppression of EGFR/ΔEGFR(2–7)-dependent ERK activation in mouse astrocytes and glioma

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

An integrated pipeline for comprehensive analysis of immune cells in human brain tumor clinical samples

WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1

Search

Quick links

Search

Filter By:

Search

Quick links